The EU's IP strategy: Enabler or barrier?
EPHA #A2MDialogues

27 October 2020



Our second dialogue in a series of online discussions on key access to medicines (A2M) priorities bringing together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.

Take part in our #A2MDialogues to share your questions and ideas and help us develop actionable #A2Msolutions for decision-makers in Europe. 

How do we ensure that IP incentives compensate and reward innovation but do not distort competition?

What lessons have we learned on IP in the response to COVID19?


Patent-driven innovation may work for profit-driven drug development but it reflects a R&I agenda which favours profit prospects, distortion of competition and market dominance. Additionally, it leads to excessive, unaffordable prices due to monopoly and can stifle meaningful innovation

As the EU prepares to present its IP strategy as well as the scenarios for a review of the legislation on orphan and paediatric medicines, join our experts and key stakeholders who will discuss what change is necessary to serve the needs of all patients while guaranteeing healthy prices and competition


Alfonso Calles-Sanchez 

Policy Officer, DG Internal Market, Industry, Entrepreneurship and SMEs (DG Growth) 

European Commission

Dimitri Eynikel

EU Policy & Advocacy Advisor 

Médecins Sans Frontières Access Campaign

Sergio Napolitano

General Counsel & External Relations Director

Medicines for Europe


Thyra de Jongh

Principal Consultant

Technopolis Group

Moderated by

Yannis Natsis

Policy Manager, Universal Access and Affordable Medicines

European Public Health Alliance

On Social Media

Find out more about the other #A2MDialogues in the series below

Unleashing meaningful innovation through regulatory reform

19 October 2020

Pharma & COVID19: Winners, losers, prospects

19 November 2020

16:00-17:00 CET

The Presidencies’ perspective on the pharmaceutical strategy: Europe’s to-do list on access to medicines

25 November 2020

16:00-17:00 CET


Yannis Natsis

Policy Manager, Universal Access and Affordable Medicines, EPHA

Get involved !

Get involved !

Sign up here to receive our updates on European health policy and invitations to our events.

Subscribe now

You have Successfully Subscribed!